Novo Nordisk (NOVOB DC) Q4 (DKK): Revenue 85.7bln (exp. 80.3bln), EBIT 36.74bln (exp. 33.6bln), Wegovy Sales 19.886bln (exp. 20.18bln). Proposed a final 2024 dividend of 7.93/shr. Not initiating a new buyback.

Commentary

2024 Results

2025 Guidance

Analysis details (06:35)

05 Feb 2025 - 06:31- Important- Source: Novo Nordisk

NOVOB.DCNovo Nordisk A/SImportantEU SessionAsian SessionImportantEU SessionAsian SessionDKKNorth AmericaDenmark

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: